HomeCompareTRUMF vs MAIN

TRUMF vs MAIN: Dividend Comparison 2026

TRUMF yields 1.42% · MAIN yields 6.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $42.27M in total portfolio value
10 years
TRUMF
TRUMF
● Live price
1.42%
Share price
$12.38
Annual div
$0.18
5Y div CAGR
75.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$616.2K
Annual income
$410,809.26
Full TRUMF calculator →
MAIN
Main Street Capital Corporation
● Live price
6.91%
Share price
$52.96
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.89M
Annual income
$35,818,348.00
Full MAIN calculator →

Portfolio growth — TRUMF vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRUMFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRUMF + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRUMF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRUMF
Annual income on $10K today (after 15% tax)
$120.65/yr
After 10yr DRIP, annual income (after tax)
$349,187.87/yr
MAIN
Annual income on $10K today (after 15% tax)
$587.42/yr
After 10yr DRIP, annual income (after tax)
$30,445,595.80/yr
At 15% tax rate, MAIN beats the other by $30,096,407.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRUMF + MAIN for your $10,000?

TRUMF: 50%MAIN: 50%
100% MAIN50/50100% TRUMF
Portfolio after 10yr
$21.75M
Annual income
$18,114,578.63/yr
Blended yield
83.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

TRUMF
No analyst data
Altman Z
4.0
Piotroski
7/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.2% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRUMF buys
0
MAIN buys
0
No recent congressional trades found for TRUMF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRUMFMAIN
Forward yield1.42%6.91%
Annual dividend / share$0.18$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR75.5%72.7%
Portfolio after 10y$616.2K$42.89M
Annual income after 10y$410,809.26$35,818,348.00
Total dividends collected$576.3K$41.85M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: TRUMF vs MAIN ($10,000, DRIP)

YearTRUMF PortfolioTRUMF Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$10,949$249.12$12,434$1,193.51$1.5KMAIN
2$12,163$447.38$16,255$2,280.05$4.1KMAIN
3$13,829$815.13$22,851$4,580.08$9.0KMAIN
4$16,318$1,520.16$35,577$9,892.59$19.3KMAIN
5$20,402$2,941.94$63,653$23,664.70$43.3KMAIN
6$27,863$6,033.08$136,601$65,054.52$108.7KMAIN
7$43,328$13,514.24$368,044$214,504.02$324.7KMAIN
8$80,829$34,468.45$1,301,668$887,987.40$1.22MMAIN
9$191,954$105,467.10$6,288,483$4,825,407.47$6.10MMAIN
10$616,200$410,809.26$42,886,603$35,818,348.00$42.27MMAIN

TRUMF vs MAIN: Complete Analysis 2026

TRUMFStock

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Full TRUMF Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this TRUMF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRUMF vs SCHDTRUMF vs JEPITRUMF vs OTRUMF vs KOTRUMF vs ARCCTRUMF vs HTGCTRUMF vs GBDCTRUMF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.